Spyre Therapeutics Inc. (NASDAQ:SYRE) shares dropped 13.7% in premarket trading on Wednesday after regulatory filings revealed significant stock sales by company insiders, including a transaction worth nearly $400 million by an investment fund affiliated with members of the board.
The disclosures raised concerns among investors about insider sentiment and prompted selling pressure in the stock.
Fairmount Fund Exits Common Stock Position
According to a Form 4 filing submitted to the U.S. Securities and Exchange Commission, Fairmount Healthcare Fund II L.P. sold 4,684,781 shares of Spyre common stock on June 23 at a price of $85.31 per share.
The transaction was valued at approximately $399.7 million and reduced the fund’s common stock ownership to zero shares.
Fairmount Healthcare Fund II L.P. is affiliated with directors of Spyre Therapeutics, making the transaction particularly notable for investors monitoring insider activity.
Sale Followed Preferred Stock Conversion
The share sale occurred after the fund converted 16,667 shares of Series B Preferred Stock into 666,680 shares of common stock.
Under the terms of the preferred securities, each Series B Preferred share is convertible into 40 common shares, subject to certain beneficial ownership limitations.
The conversion and subsequent sale formed part of the broader reduction in the fund’s exposure to Spyre’s common equity.
Board Connections Draw Investor Attention
Fairmount Funds Management LLC serves as investment manager for Fairmount Healthcare Fund II L.P.
The firm is managed by Peter Harwin and Tomas Kiselak, with Kiselak currently serving as a member of Spyre Therapeutics’ board of directors.
Given the board-level connection, investors closely scrutinized the transaction as a potential indicator of insider views regarding valuation or future prospects.
Director Also Sells Shares
In a separate filing, Spyre director Michael Thomas Henderson disclosed the sale of 20,000 shares on June 22 at a price of $100 per share.
The transaction generated proceeds of approximately $2 million.
The filing stated that the sale was conducted under a Rule 10b5-1 trading plan that had been adopted on February 6, 2026.
Following the transaction, Henderson continued to own 68,606 shares of Spyre common stock.
Significant Preferred Share Position Remains
Despite the disposal of its common stock holdings, Fairmount Healthcare Fund II L.P. retains a sizeable position through preferred securities.
Following the reported transactions, the fund continues to own 346,045 shares of Series A Preferred Stock.
Those securities are convertible into 13,841,800 shares of common stock under conversion terms similar to those governing the Series B Preferred Stock and remain subject to beneficial ownership restrictions.
Investors React to Insider Activity
Large insider transactions often attract investor attention, particularly when they involve board-affiliated shareholders and substantial dollar amounts.
While the filings do not indicate the reasons behind the sales, the scale of the transactions contributed to negative sentiment surrounding the stock and weighed on shares in premarket trading.
Investors will likely continue monitoring future insider activity and any additional disclosures regarding the remaining preferred share holdings as they assess the implications for Spyre Therapeutics’ shareholder base and stock performance.